Rituximab
| Rituximab | |
|---|---|
| Term | Rituximab |
| Short definition | Rituximab - (pronounced) (rih-TUK-sih-mab) drug used alone or with other drugs under the brand names Riabni, Rituxan, Ruxience, and Truxima to treat certain types of B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute B-cell leukemia who are CD20 positive. Rituximab is also being studied to treat other diseases and cancers. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Rituximab - (pronounced) (rih-TUK-sih-mab) drug used alone or with other drugs under the brand names Riabni, Rituxan, Ruxience, and Truxima to treat certain types of B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute B-cell leukemia who are CD20 positive. Rituximab is also being studied to treat other diseases and cancers. Rituximab attaches to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This can help the immune system kill cancer cells. Rituximab is a type of monoclonal antibody
External links
- Medical encyclopedia article on Rituximab
- Wikipedia's article - Rituximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski